Posts Archive for July 2010

Cipro use can lead to super-anthrax

Jul.26, 2010

The massive use of antibiotics against anthrax can lead to emergence of super-virus, a strain of anthrax that is resistant to treatment with currently known remedies.

The U.S. government, in order to prevent an epidemic of anthrax, purchased in large quantities antibiotic Cipro (ciprofloxacin). Tens of thousands of U.S. citizens take this medicine as a preventive treatment. However, unjustified administration of powerful antibiotics develops “immunity” in many pathogenic viruses, and the same could happen with anthrax. In addition, under such conditions increases the likelihood of the possibility of purposeful development of a form of anthrax resistant to medicines that threatens a catastrophe.

Levaquin: more therapeutic indications

Jul.26, 2010

Currently in clinical practice are becoming more common so-called respiratory fluoroquinolones, which on one hand, preserve the activity of the early fluoroquinolones (eg ciprofloxacin) against gram-negative organisms, but on the other – are more active against pneumococci and atypical bacteria.

Levofloxacin, the active component of Levaquin, is the most studied substance among respiratory fluoroquinolones. It has been prescribed to more than 300 million patients worldwide. A number of clinical studies has confirmed Levaquin’s high efficacy and safety both in the traditional indications for this group of antibiotics, such as acute sinusitis, exacerbation of chronic bronchitis, community-acquired pneumonia, urinary tract infections, and in some other diseases: nosocomial pneumonia, chronic bacterial prostatitis.